ACME Laboratories (DHA:ACMELAB) LT-Debt-to-Total-Asset: 0.12 (As of Mar. 2026)

What is ACME Laboratories LT-Debt-to-Total-Asset?

ACME Laboratories DHA:ACMELAB +0.36% 90 LT-Debt-to-Total-Asset is 0.12 as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 90/100 and a GF Value™ of BDT125.51 (Possible Value Trap). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ACME Laboratories's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.12.

ACME Laboratories's long-term debt to total assets ratio increased from Dec. 2024 (0.12) to Mar. 2026 (0.12). It may suggest that ACME Laboratories is progressively becoming more dependent on debt to grow their business.

ACME Laboratories (DHA:ACMELAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ACME Laboratories LT-Debt-to-Total-Asset Related Terms

ACME Laboratories LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories LT-Debt-to-Total-Asset Chart

ACME Laboratories Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.13

0.14

0.10

0.12

ACME Laboratories Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.11	0.13	0.12	0.12

90GF Score

ACME Laboratories Ltd DHA:ACMELAB

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

ACME Laboratories LT-Debt-to-Total-Asset Calculation

ACME Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )	/	Total Assets (A: Jun. 2024 )
	=	6798.19	/	55622.164
	=	0.12

ACME Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	7099.997	/	59535.015
	=	0.12

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.12 mean?

ACME Laboratories (DHA:ACMELAB) has a LT-Debt-to-Total-Asset of 0.12 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on ACME Laboratories and its competitors.

Is ACME Laboratories' LT-Debt-to-Total-Asset too high?

ACME Laboratories' current LT-Debt-to-Total-Asset is 0.12. Overall, ACME Laboratories has a GF Score™ of 90/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does ACME Laboratories' LT-Debt-to-Total-Asset compare to ZTS and UTHR?

ACME Laboratories' LT-Debt-to-Total-Asset of 0.12 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on ACME Laboratories and its competitors. ACME Laboratories's current LT-Debt-to-Total-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is ACME Laboratories stock overvalued right now?

Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT125.51, compared to a current price of BDT84.50 — trading 32.7% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.12. ACME Laboratories' overall GF Score™ is 90/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current LT-Debt-to-Total-Asset is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT84.50 is trading 32.7% below its estimated GF Value™ of BDT125.51. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

LT-Debt-to-Total-Asset: 0.12
GF Value™: BDT125.51 vs. price of BDT84.50 (32.7% below fair value)
GF Score™: 90/100 with 7 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACME Laboratories Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies DHA:BEACONPHAR DHA:ASIATICLAB DHA:ORIONINFU DHA:TECHNODRUG DHA:CENTRALPHL DHA:RENATA XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207

Website https://www.acmeglobal.com

ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.

90GF Score

Get the complete analysis for DHA:ACMELAB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT84.50

Price

BDT125.51

GF Value

View DHA:ACMELAB Analysis

See LT-Debt-to-Total-Asset data for all stocks →